Abstract

Patients with higher-risk myelodysplastic syndrome (HR-MDS) are defined by the original or revised International Prognostic Scoring System and specific genetic features. Treatment of HR-MDS is challenging. Allogeneic hematopoietic stem cell transplantation, the only curative approach, is feasible in a minority of fit or intermediate fitness patients aged <70 to 75 years who are willing to face the risks of the procedure. Response to azacitidine and decitabine, the only approved drugs for HR-MDS and considered the standard of care, is partial and transient in most patients. The development of novel more personalized and efficient drugs is an unmet medical need. During the last decade, there have been substantial advances in understanding the multiple molecular, cellular, and immunological disturbances involved in the pathogenesis of myelodysplastic syndrome. As a result, a number of clinical and translational studies of new more focused treatment approaches for HR-MDS patients are underway. In contrast to acute myeloid leukemia, they have not resulted in any new drug approval. This review addresses the benefits and limitations of current treatment alternatives, offers a practical individualized treatment approach, and summarizes the clinical trials in progress for HR-MDS.

References

References
1.
Greenberg
P
,
Cox
C
,
LeBeau
MM
, et al
.
International scoring system for evaluating prognosis in myelodysplastic syndromes
.
Blood
.
1997
;
89
(
6
):
2079
-
2088
.
2.
Greenberg
PL
,
Tuechler
H
,
Schanz
J
, et al
.
Revised international prognostic scoring system for myelodysplastic syndromes
.
Blood
.
2012
;
120
(
12
):
2454
-
2465
.
3.
Pfeilstöcker
M
,
Tuechler
H
,
Sanz
G
, et al
.
Time-dependent changes in mortality and transformation risk in MDS
.
Blood
.
2016
;
128
(
7
):
902
-
910
.
4.
Guralnik
JM
,
Simonsick
EM
,
Ferrucci
L
, et al
.
A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission
.
J Gerontol
.
1994
;
49
(
2
):
M85
-
M94
.
5.
Neo
J
,
Fettes
L
,
Gao
W
,
Higginson
IJ
,
Maddocks
M
.
Disability in activities of daily living among adults with cancer: a systematic review and meta-analysis
.
Cancer Treat Rev
.
2017
;
61
:
94
-
106
.
6.
Bellera
CA
,
Rainfray
M
,
Mathoulin-Pélissier
S
, et al
.
Screening older cancer patients: first evaluation of the G-8 geriatric screening tool
.
Ann Oncol
.
2012
;
23
(
8
):
2166
-
2172
.
7.
Palumbo
A
,
Bringhen
S
,
Mateos
M-V
, et al
.
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
.
Blood
.
2015
;
125
(
13
):
2068
-
2074
.
8.
Bonanad
S
,
De la Rubia
J
,
Gironella
M
, et al
;
GAH Group
.
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
.
J Geriatr Oncol
.
2015
;
6
(
5
):
353
-
361
.
9.
Deschler
B
,
Ihorst
G
,
Platzbecker
U
, et al
.
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
.
Haematologica
.
2013
;
98
(
2
):
208
-
216
.
10.
Della Porta
MG
,
Malcovati
L
,
Strupp
C
, et al
.
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
.
Haematologica
.
2011
;
96
(
3
):
441
-
449
.
11.
Charlson
ME
,
Pompei
P
,
Ales
KL
,
MacKenzie
CR
.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
.
J Chronic Dis
.
1987
;
40
(
5
):
373
-
383
.
12.
Sorror
ML
,
Sandmaier
BM
,
Storer
BE
, et al
.
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
.
J Clin Oncol
.
2007
;
25
(
27
):
4246
-
4254
.
13.
Cutler
CS
,
Lee
SJ
,
Greenberg
P
, et al
.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
.
Blood
.
2004
;
104
(
2
):
579
-
585
.
14.
Koreth
J
,
Pidala
J
,
Pérez
WS
, et al
.
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis
.
J Clin Oncol
.
2013
;
31
(
21
):
2662
-
2670
.
15.
Platzbecker
U
,
Schetelig
J
,
Finke
J
, et al
;
Groupe Francophone des Myelodysplasies
.
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine
.
Biol Blood Marrow Transplant
.
2012
;
18
(
9
):
1415
-
1421
.
16.
Kroeger
N
,
Sockel
K
,
Wolschke
C
, et al
.
Prospective multicenter phase 3 study comparing 5-azacytidine (5-aza) induction followed by allogeneic stem cell transplantation versus continuous 5-aza according to donor availability in elderly MDS patients (55-70 years) (VidazaAllo study)
.
Blood
.
2018
;
132
(
suppl 1
):
208
.
17.
Shaffer
BC
,
Ahn
KW
,
Hu
Z-H
, et al
.
Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
.
J Clin Oncol
.
2016
;
34
(
16
):
1864
-
1871
.
18.
de Witte
T
,
Bowen
D
,
Robin
M
, et al
.
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
.
Blood
.
2017
;
129
(
13
):
1753
-
1762
.
19.
Della Porta
MG
,
Gallì
A
,
Bacigalupo
A
, et al
.
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation
.
J Clin Oncol
.
2016
;
34
(
30
):
3627
-
3637
.
20.
Yoshizato
T
,
Nannya
Y
,
Atsuta
Y
, et al
.
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
.
Blood
.
2017
;
129
(
17
):
2347
-
2358
.
21.
Lindsley
RC
,
Saber
W
,
Mar
BG
, et al
.
Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation
.
N Engl J Med
.
2017
;
376
(
6
):
536
-
547
.
22.
Alessandrino
EP
,
Della Porta
MG
,
Pascutto
C
,
Bacigalupo
A
,
Rambaldi
A
.
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?
J Clin Oncol
.
2013
;
31
(
21
):
2761
-
2762
.
23.
Scott
BL
,
Storer
B
,
Loken
MR
,
Storb
R
,
Appelbaum
FR
,
Deeg
HJ
.
Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome
.
Biol Blood Marrow Transplant
.
2005
;
11
(
1
):
65
-
73
.
24.
Damaj
G
,
Mohty
M
,
Robin
M
, et al
.
Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire
.
Biol Blood Marrow Transplant
.
2014
;
20
(
9
):
1349
-
1355
.
25.
Gerds
AT
,
Gooley
TA
,
Estey
EH
,
Appelbaum
FR
,
Deeg
HJ
,
Scott
BL
.
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS
.
Biol Blood Marrow Transplant
.
2012
;
18
(
8
):
1211
-
1218
.
26.
Damaj
G
,
Duhamel
A
,
Robin
M
, et al
.
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
.
J Clin Oncol
.
2012
;
30
(
36
):
4533
-
4540
.
27.
Welch
JS
,
Petti
AA
,
Miller
CA
, et al
.
TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes
.
N Engl J Med
.
2016
;
375
(
21
):
2023
-
2036
.
28.
Scott
BL
,
Pasquini
MC
,
Logan
BR
, et al
.
Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
.
J Clin Oncol
.
2017
;
35
(
11
):
1154
-
1161
.
29.
Kröger
N
,
Iacobelli
S
,
Franke
G-N
, et al
.
Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial)
.
J Clin Oncol
.
2017
;
35
(
19
):
2157
-
2164
.
30.
Adhikari
J
,
Sharma
P
,
Bhatt
VR
.
Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies
.
Future Oncol
.
2015
;
11
(
23
):
3175
-
3185
.
31.
Rambaldi
A
,
Grassi
A
,
Masciulli
A
, et al
.
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
.
Lancet Oncol
.
2015
;
16
(
15
):
1525
-
1536
.
32.
Beelen
D
,
Markiewicz
M
,
Stelljes
M
, et al
.
Final evaluation of a clinical phase III trial comparing treosulfan to busulfan-based conditioning therapy prior to allogeneic hematopoietic stem cell transplantation of adult acute myeloid leukemia and myelodysplastic syndrome patients ineligible to standard myeloablative regimens
.
Biol Blood Marrow Transplant
.
2019
;
25
(
3
):
S3
.
33.
Ciurea
SO
,
Zhang
M-J
,
Bacigalupo
AA
, et al
.
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
.
Blood
.
2015
;
126
(
8
):
1033
-
1040
.
34.
Eapen
M
,
Rocha
V
,
Sanz
G
, et al
;
National Cord Blood Program of the New York Blood Center
.
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis
.
Lancet Oncol
.
2010
;
11
(
7
):
653
-
660
.
35.
Robinson
TM
,
Fuchs
EJ
,
Zhang
MJ
, et al
;
Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research
.
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?
Blood Adv
.
2018
;
2
(
11
):
1180
-
1186
.
36.
Robin
M
,
Porcher
R
,
Ruggeri
A
, et al
.
HLA-mismatched donors in patients with myelodysplastic syndrome: An EBMT Registry analysis
.
Biol Blood Marrow Transplant
.
2019
;
25
(
1
):
114
-
120
.
37.
Guardiola
P
,
Runde
V
,
Bacigalupo
A
, et al
;
Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group
.
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
.
Blood
.
2002
;
99
(
12
):
4370
-
4378
.
38.
del Cañizo
MC
,
Martínez
C
,
Conde
E
, et al
;
Grupo Español de Trasplante Hematopoyético
.
Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry
.
Bone Marrow Transplant
.
2003
;
32
(
10
):
987
-
992
.
39.
Lee
SJ
,
Logan
B
,
Westervelt
P
, et al
.
Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial
.
JAMA Oncol
.
2016
;
2
(
12
):
1583
-
1589
.
40.
Adhikari
J
,
Sharma
P
,
Bhatt
VR
.
Optimal graft source for allogeneic hematopoietic stem cell transplant: bone marrow or peripheral blood?
Future Oncol
.
2016
;
12
(
15
):
1823
-
1832
.
41.
Genovese
G
,
Jaiswal
S
,
Ebert
BL
,
McCarroll
SA
.
Clonal hematopoiesis and blood-cancer risk
.
N Engl J Med
.
2015
;
372
(
11
):
1071
-
1072
.
42.
Jaiswal
S
,
Fontanillas
P
,
Flannick
J
, et al
.
Age-related clonal hematopoiesis associated with adverse outcomes
.
N Engl J Med
.
2014
;
371
(
26
):
2488
-
2498
.
43.
Frick
M
,
Chan
W
,
Arends
CM
, et al
.
Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation
.
J Clin Oncol
.
2019
;
37
(
5
):
375
-
385
.
44.
Kröger
N
,
Zabelina
T
,
de Wreede
L
, et al
;
MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
.
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings
.
Leukemia
.
2013
;
27
(
3
):
604
-
609
.
45.
Guièze
R
,
Damaj
G
,
Pereira
B
, et al
.
Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies
.
Biol Blood Marrow Transplant
.
2016
;
22
(
2
):
240
-
247
.
46.
Schroeder
T
,
Rachlis
E
,
Bug
G
, et al
.
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions–a retrospective multicenter analysis from the German Cooperative Transplant Study Group
.
Biol Blood Marrow Transplant
.
2015
;
21
(
4
):
653
-
660
.
47.
de Lima
M
,
Oran
B
,
Champlin
RE
, et al
.
CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes
.
Biol Blood Marrow Transplant
.
2018
;
24
(
10
):
2017
-
2024
.
48.
Platzbecker
U
,
Middeke
JM
,
Sockel
K
, et al
.
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
.
Lancet Oncol
.
2018
;
19
(
12
):
1668
-
1679
.
49.
Duncavage
EJ
,
Jacoby
MA
,
Chang
GS
, et al
.
Mutation clearance after transplantation for myelodysplastic syndrome
.
N Engl J Med
.
2018
;
379
(
11
):
1028
-
1041
.
50.
Silverman
LR
,
Demakos
EP
,
Peterson
BL
, et al
.
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B
.
J Clin Oncol
.
2002
;
20
(
10
):
2429
-
2440
.
51.
Kantarjian
H
,
Issa
J-PJ
,
Rosenfeld
CS
, et al
.
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
.
Cancer
.
2006
;
106
(
8
):
1794
-
1803
.
52.
Fenaux
P
,
Mufti
GJ
,
Hellström-Lindberg
E
, et al
;
International Vidaza High-Risk MDS Survival Study Group
.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
.
Lancet Oncol
.
2009
;
10
(
3
):
223
-
232
.
53.
Lübbert
M
,
Suciu
S
,
Baila
L
, et al
.
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
.
J Clin Oncol
.
2011
;
29
(
15
):
1987
-
1996
.
54.
Fenaux
P
,
Gattermann
N
,
Seymour
JF
, et al
.
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
.
Br J Haematol
.
2010
;
149
(
2
):
244
-
249
.
55.
Seymour
JF
,
Fenaux
P
,
Silverman
LR
, et al
.
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
.
Crit Rev Oncol Hematol
.
2010
;
76
(
3
):
218
-
227
.
56.
Almasri
J
,
Alkhateeb
HB
,
Firwana
B
, et al
.
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
.
Syst Rev
.
2018
;
7
(
1
):
144
.
57.
Mozessohn
L
,
Cheung
MC
,
Fallahpour
S
, et al
.
Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada
.
Br J Haematol
.
2018
;
181
(
6
):
803
-
815
.
58.
Bernal
T
,
Martínez-Camblor
P
,
Sánchez-García
J
, et al
;
Spanish Society of Hematology
.
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
.
Leukemia
.
2015
;
29
(
9
):
1875
-
1881
.
59.
Itzykson
R
,
Thépot
S
,
Quesnel
B
, et al
;
Groupe Francophone des Myelodysplasies(GFM)
.
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
.
Blood
.
2011
;
117
(
2
):
403
-
411
.
60.
Dinmohamed
AG
,
van Norden
Y
,
Visser
O
, et al
.
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
.
Leukemia
.
2015
;
29
(
12
):
2449
-
2451
.
61.
Kantarjian
H
,
Oki
Y
,
Garcia-Manero
G
, et al
.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
.
Blood
.
2007
;
109
(
1
):
52
-
57
.
62.
Kuendgen
A
,
Müller-Thomas
C
,
Lauseker
M
, et al
.
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
.
Oncotarget
.
2018
;
9
(
45
):
27882
-
27894
.
63.
Takahashi
K
,
Patel
K
,
Bueso-Ramos
C
, et al
.
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
.
Oncotarget
.
2016
;
7
(
12
):
14172
-
14187
.
64.
Itzykson
R
,
Kosmider
O
,
Cluzeau
T
, et al
;
Groupe Francophone des Myelodysplasies (GFM)
.
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
.
Leukemia
.
2011
;
25
(
7
):
1147
-
1152
.
65.
Idossa
D
,
Lasho
TL
,
Finke
CM
, et al
.
Mutations and karyotype predict treatment response in myelodysplastic syndromes
.
Am J Hematol
.
2018
;
93
(
11
):
1420
-
1426
.
66.
Sébert
M
,
Renneville
A
,
Bally
C
, et al
;
Groupe Francophone des Myélodysplasies (GFM)
.
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
.
Haematologica
.
2019
;
104
(
8
):
1565
-
1571
.
67.
Savona
MR
,
Odenike
O
,
Amrein
PC
, et al
.
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
.
Lancet Haematol
.
2019
;
6
(
4
):
e194
-
e203
.
68.
Sekeres
MA
,
Othus
M
,
List
AF
, et al
.
Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117
.
J Clin Oncol
.
2017
;
35
(
24
):
2745
-
2753
.
69.
Dickinson
M
,
Cherif
H
,
Fenaux
P
, et al
;
SUPPORT study investigators
.
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
.
Blood
.
2018
;
132
(
25
):
2629
-
2638
.
70.
DiNardo
CD
,
Pratz
K
,
Pullarkat
V
, et al
.
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
.
Blood
.
2019
;
133
(
1
):
7
-
17
.
71.
DiNardo
CD
,
Watts
JM
,
Stein
EM
, et al
.
Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: results from a phase 1 dose escalation and expansion study
.
Blood
.
2018
;
132
(
suppl 1
):
1812
.
72.
Sallman
DA
,
DeZern
AE
,
Steensma
DP
, et al
.
Phase 1b/2 combination study of APR-246 and azacitidine (aza) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
.
Blood
.
2018
;
132
(
suppl 1
):
3901
.
73.
Garcia-Manero
G
,
Sasaki
K
,
Montalban-Bravo
G
, et al
.
A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)
.
Blood
.
2018
;
132
(
suppl 1
):
465
.
74.
Daver
N
,
Boddu
P
,
Garcia-Manero
G
, et al
.
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
.
Leukemia
.
2018
;
32
(
5
):
1094
-
1105
.
75.
Kubasch
AS
,
Schulze
F
,
Gotze
KS
, et al
.
Anti-CD123 targeted therapy with talacotuzumab in advanced MDS and AML after failing hypomethylating agents - final results of the Samba trial
.
Blood
.
2018
;
132
(
suppl 1
):
4045
.
76.
Garcia-Manero
G
,
Fenaux
P
,
Al-Kali
A
, et al
;
ONTIME study investigators
.
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
.
Lancet Oncol
.
2016
;
17
(
4
):
496
-
508
.
77.
Navada
SC
,
Garcia-Manero
G
,
Atallah
EL
, et al
.
Phase 2 expansion study of oral rigosertib combined with azacitidine (aza) in patients (pts) with higher-risk (HR) myelodysplastic syndromes (MDS): efficacy and safety results in HMA treatment naive and relapsed (Rel)/Refractory (Ref) patients
.
Blood
.
2018
;
132
(
suppl 1
):
230
.
78.
Voso
MT
,
Leone
G
,
Piciocchi
A
, et al
.
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study
.
Ann Oncol
.
2017
;
28
(
7
):
1547
-
1553
.
You do not currently have access to this content.